COVID-19 Drug Discovery Assays

Reaction Biology understands the increasingly urgent need to address the COVID-19 situation with clinically approved therapeutic drugs. To support the drug discovery community in the challenge to identify efficacious COVID-19 drugs, we have developed specific assays to block SARS-CoV-2 virus entry and replication.

Our COVID-19 therapeutic drug testing service is available for pharmaceutical companies and medical researchers worldwide. Get in touch with the business development manager assigned to your country today.

We offer two assay formats designated to target SARS-CoV-2 replication. See links below.

Beside virus replication drugs are also developed to alleviate COVID-19 symptoms with a variety of targets that are well established for medical treatment:

Target name Target family Assay format
ABL Kinase ³³PanQinase, HotSpot, NanoBRET, Recombinant Protein
AXL Kinase ³³PanQinase, HotSpot, NanoBRET, Cellular Phosphorylation Assay, Recombinant Protein
BRD4 Reader Domain AlphaScreen, TSA, ITC, MST, SPR
BTK Kinase ³³PanQinase, HotSpot, NanoBRET, Recombinant Protein
CDK4 Kinase ³³PanQinase, HotSpot, NanoBRET, Recombinant Protein
CDK6 Kinase ³³PanQinase, HotSpot, NanoBRET, Recombinant Protein
EGFR Kinase ³³PanQinase, HotSpot, NanoBRET, Cellular Phosphorylation Assay, Recombinant Protein
JAK1 Kinase ³³PanQinase, HotSpot, Recombinant Protein
JAK2 Kinase ³³PanQinase, HotSpot, Recombinant Protein
JAK3 Kinase ³³PanQinase, HotSpot, NanoBRET, Recombinant Protein
PP1A Phosphatase Fluorescence-based Assay
SYK Kinase ³³PanQinase, HotSpot, NanoBRET, Recombinant Protein
TYK2 Kinase ³³PanQinase, HotSpot, NanoBRET

Source:
E Pairo-Castineira et al., Nature, 2020. Genetic mechanisms of critical illness in COVID-19.
Y Qiao et al., PNAS, 2020. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2.
E Weisberg et al., Pharm Res., 2020. Repurposing of Kinase Inhibitors for Treatment of COVID-19.

 

The SARS-CoV-2 Spike protein and ACE2 binding assay is used to measure the direct binding of potential therapeutics to the Spike protein receptor-binding domain or ACE2 to determine the kinetics of the interaction or to measure whether the test molecule(s) disrupt the Spike/ACE2 interaction.

We perform this assay at our Malvern, PA facility using surface plasmon resonance (SPR) technology. Our team uses state-of-the-art Biacore 8K units that ensure accurate and comprehensive results. The standard turnaround time is two weeks.

We offer compound screening assays targeting proteases that are essential for SARS-CoV-2 virus entry and replication. These target proteases include ACE2, TMPRSS2, Main Protease (Mpro), PLpro and more.

Our protease assay screening service comprises fluorescence-based activity assays for low and large-scale screening, and for off-target analysis via full protease panel screening.